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Abstract
Thephysiologic response to changes in cellular oxygen
tension is ultimately governed by a heterodimeric tran-
scription factor called hypoxia-inducible factor (HIF),
which, in adaptation to compromised oxygen availabil-
ity, transactivates a myriad of genes, including those
responsible for de novo vascularization, production of
oxygen-carrying red blood cells, and anaerobic metab-
olism. Accumulation of HIF is observed inmost types of
solid tumors and is frequently associated with poor
prognosis and disease progression, underscoring the
importance and relevance of HIF in cancer. The protein
stability and, thereby, the activity of HIF are principally
regulated by the von Hippel-Lindau (VHL) tumor-
suppressor–containing E3 ubiquitin ligase complex
(ECV) that targets the catalytic subunit HIFA for oxygen-
dependent ubiquitin-mediated destruction. Individ-
uals who inherit germline VHL mutation develop VHL
disease, which is characterized by the development of
hypervascular tumors in multiple yet specific organs.
This review will examine recent progress in our under-
standing of the molecular mechanisms governing the
function of ECV and the significance of consequential
regulation of HIF in oncogenesis.
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History of von Hippel-Lindau (VHL) Disease
VHL disease (OMIM 193300) is a familial cancer syndrome
that was first described in the medical literature by a German
ophthalmologist Eugen von Hippel, a Swedish neuropa-
thologist Arvid Lindau, and a British surgeon E. Treacher
Collins at the turn of the 20th century [1]. VHL disease is es-
timated to affect 1 in 36,000 individuals, displaying no ethnic,
racial, cultural, or sexual bias, and is characterized by the
presence of hypervascular tumors in multiple organs, in-
cluding the central nervous system (cerebellum, brainstem,
and spinal cord), retina, pancreas, adrenal gland, endo-
lymphatic sac of the inner ear, epididymis (male), broad
ligament (female), and kidneys [2]. Although most of the tu-
mors associated with VHL disease are benign, kidney cancer
is malignant and is of the clear cell type, which accounts for
75% of kidney cancers. Kidney cancer remains as the prin-
cipal cause of morbidity and mortality for VHL patients [2,3].
VHL disease is caused by the inheritance of a defective copy
of the VHL gene, which was identified by Latif et al. [4] (from the
National Institutes of Health and Oxford University). Tumors
arise in a VHL kindred when the remaining wild-type allele is
mutated or lost in a susceptible cell. Thus, on a cellular level,
VHL disease has an autosomal recessive pattern of inheritance
requiring inactivation of both alleles. However, clinically, it is
perceived as an autosomal-dominant disease because the
occurrence of the second inactivating mutation on the wild-type
allele is virtually guaranteed [2]. VHL inactivation has been
established as an early and requisite step in renal clear-cell
carcinoma (RCC) pathogenesis, as the loss of heterozygosity in
the remaining wild-type VHL allele in the proximal renal tubular
epithelial cells has been documented in early premalignant
renal cysts in VHL patients [5]. In keeping with the two-hit model
of Knudson [6], biallelic inactivation of the VHL gene is also
observed in the majority of sporadic RCC, establishing VHL as
the critical ‘‘gatekeeper’’ of the renal epithelium.
The VHL gene consists of three exons, producing two tran-
scripts that are translated into three proteins. The first VHL
mRNA of approximately 4.5 kb contains exons 1 to 3 and is
translated into two proteins due to an internal translational ini-
tiation start site at codon 54 [7–9]. The larger product is a
213-amino-acid protein of approximately 24 to 30 kDa (VHL30),
and the shorter product is an 18- to 19-kDa isoform (VHL19) of
160 amino acids. The secondVHLmRNA contains exons 1 and
3 due to alternative splicing. Tumors that exclusively produce
this exon 2–less transcript have been identified, suggesting
that the protein product encoded by this alternatively spliced
transcript is defective in tumor-suppressor activity [10]. Further-
more, VHL mRNA expression is ubiquitous and, thus, is not
restricted to specific tissue types that have been associated
with VHL disease [11,12]. In addition, the VHL expression
pattern in fetal kidneys suggests a role in normal renal tubular
development and differentiation [11,12].
VHL disease is classified into categories, depending on
a patient’s likelihood of developing pheochromocytoma [2].
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Type 1 patients have a low risk of developing pheochromo-
cytoma, but present with RCC. Type 2 patients have a high
risk of developing pheochromocytoma, with type 2A patients
having a low risk of developing RCC but with type 2B patients
having a high risk of developing RCC. Type 1, type 2A, and
type 2B patients also develop the two cardinal features of
VHL disease: cerebellar and retinal hemangioblastomas.
Type 2C patients develop pheochromocytoma exclusively.
The mutations associated with type 1 disease are deletions,
microinsertions, and nonsense mutations, whereas type 2
patients typically present with missense mutations.
VHL19 Is Not VHL30, But Is It a Tumor Suppressor?
The human VHL gene is translated into two wild-type VHL
proteins: VHL30 and the internally translated VHL19 [7–9].
Reconstitution of RCC cells with either VHL30 or VHL19
suppressed tumor development in a nude mouse xenograft
assay [8,9,13,14]. This observation led to the belief that
VHL30 and VHL19 have overlapping functions as tumor
suppressors. However, recent findings have challenged this
notion. Firstly, VHL mutations associated with tumor devel-
opment have been identified throughout an open reading
frame, including several mutations within the first 53 amino
acids that are predicted to produce functional VHL19
[15–17]. Secondly, VHL30 and VHL19 were shown to have
different subcellular localization profiles. Although VHL30 is
found in the nuclear, cytosolic, and membranous [asso-
ciated with endoplasmic reticulum (ER)] fractions, VHL19 is
excluded from the membrane fraction [7,18–20]. Although
the functional significance of VHL30 association with ER is
unclear, it may be related to the ability of VHL30, but not
VHL19, to bind fibronectin and its requirement to promote
the assembly of fibronectin extracellular matrix (ECM)
[20,21]. Thirdly, Stickle et al. [22] have shown that mutant
VHL-expressing RCC cells with intact hypoxia-inducible fac-
tor (HIF) regulation but defective fibronectin ECM assembly
formed tumors in an SCID mouse xenograft assay, under-
scoring the significance of proper fibronectin ECM in the
development of RCC. In addition, phosphorylation of the
N-terminal acidic domain, which is lacking in VHL19, through
casein kinase 2 was shown to attenuate the binding of
VHL30 to fibronectin [23]. This result suggests that, although
the first 53 amino acids of VHL30 are required for binding
fibronectin, phosphorylation of this region either prevents
the recruitment of fibronectin or releases bound fibronectin
in the ER. In light of these recent findings, the question of
whether VHL19 can support a tumor-suppressor role needs
to be revisited.
ECV Complex and the Ubiquitin-Mediated Destruction
of HIF
VHL (VHL30 or VHL19) is a component of an E3 ubiquitin
ligase complex called ECV, consisting of elongin B, elongin C,
Rbx1 (also known as ROC1/Hrt1), and Cullin 2 (Cul2) [3].
Structurally and functionally, ECV is analogous to the Skp1/
Cdc53/F-box protein (SCF) complex. VHL consists of two
functional domains: a and b [24]. The a domain is required
for binding elongin C, which binds to Cul2 to nucleate the ECV
complex. The b domain acts as a substrate-recognition/dock-
ing site. Disease-associated mutations in the VHL kindred
frequently map to surface residues on either domain, suggest-
ing that these domains are important for the tumor-suppressor
function of VHL [24]. Rbx1, which is recruited by Cul2, is
thought to recognize a cognate E2 ubiquitin-conjugating en-
zyme required for the E3 ligase function of ECV [25–27].
Several putative substrates of ECV, including atypical
protein kinase C [28], VHL-interacting deubiquitinating en-
zyme [29], and the seventh (Rpb7) [30] and the large (Rbp1)
[31] subunits of RNA polymerase II, have been identified.
However, not every protein bound by VHL is subjected to
polyubiquitylation. These include SP1 transcription factor
[32], VHL-associated KRAB-A domain–containing protein
transcription repressor [33], microtubules [34], and fibronec-
tin [20,35]. These findings have led to the notion that VHL has
multiple functions from transcription, to cytoskeletal organi-
zation, to ECM assembly through ubiquitin-dependent and
ubiquitin-independent mechanisms. Although these are in-
triguing possibilities, especially with growing evidence sup-
porting the role of VHL in the assembly of fibronectin ECM,
whether other aforementioned functions are physiologically
relevant and/or necessary for the tumor-suppressor activity
of VHL remains to be (further) proven.
What is widely accepted as a bona fide ECV substrate is
the a subunit of HIFa [36,37]. HIF is the major transcription
factor that transactivates a number (more than 60 and grow-
ing) of hypoxia-inducible genes, including vascular endothe-
lial growth factor (VEGF; also known as vascular permeability
factor), erythropoietin (EPO), and glucose transporter-1
(GLUT1), to promote angiogenesis, production of oxygen-
carrying erythrocytes, and anaerobic metabolism, respec-
tively, in adaptation to reduced oxygen tension [38,39]. There
are three members of the HIF family (HIF-1, HIF-2, and HIF-
3) in humans [40,41]. HIF is a heterodimeric complex con-
sisting of a and b subunits. The b subunit [also known as aryl
hydrocarbon receptor nuclear translocator (ARNT)] is abun-
dantly expressed independent of oxygen tension, whereas
the a subunit is oxygen labile. Specifically, the a subunit is
ubiquitylated on a stretch of residues within the oxygen-
dependent degradation (ODD) domain and, consequently,
is targeted for degradation through the 26S proteasome [42].
Under hypoxia, HIFa is stabilized and binds to the common
ARNT to form an active HIF complex, which binds to hypoxia-
responsive elements (HREs)within the promoter/enhancer of
hypoxia-inducible genes. Thus, HIF regulation occurs at the
level of the a subunit.
VHL, through its substrate-binding b domain, recruits
the HIFa subunit for oxygen-dependent ubiquitylation
[36,37,43,44]. In the presence of oxygen, HIFa is hydroxyl-
ated on conserved prolines (P) at positions 402 and 564 (the
number according toHIF-1a) within theODDdomain by prolyl
hydroxylase domain (PHD)–containing enzymes [45,46].
P564 hydroxylation is both necessary and sufficient for
the binding of HIFa ODD to VHL [45,46]. Thus, ubiquitin-
mediated destruction of HIFa only occurs in the presence of
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oxygen. Accordingly, under hypoxia, HIFa is no longer prolyl-
hydroxylated and thus escapes recognition by VHL. The
now stabile HIFa dimerizes with ARNT to bind HREs to the
trigger transcriptional activation of numerous hypoxia-
inducible genes.
In addition, a conserved C-terminal asparagine at position
803 on HIF-1a is hydroxylated by the factor-inhibiting HIF-1
enzyme in the presence of oxygen [47–49]. Unlike prolyl
hydroxylation, which induces VHL binding to HIFa, asparagyl
hydroxylation prevents the recruitment of p300/CBP tran-
scriptional coactivators to HIFa. Thus, asparagyl hydroxyl-
ation of HIF-1a attenuates the transcription of HIF target
genes [50,51]. This would suggest that there are, at a
minimum, two mechanisms that negatively regulate the ex-
pression of hypoxia-inducible genes under normoxia [1]:
oxygen-dependent ubiquitylation of HIFa through ECV and
[2] the inhibition of p300/CBP recruitment in any remaining
HIFa that has evaded destruction by ECV.
Several lines of evidence support the significance of the
VHL regulation of HIF in cancer. VHL-associated tumors are
highly vascularized, displaying overproduction of angiogenic
peptides, such as VEGF, which is one of many HIF-mediated
genes. In addition, VHL-defective cells express inordinately
high levels of numerous hypoxia-inducible transcripts even
under normoxic conditions [14,36,52–54]. Reconstitution of
cells devoid of VHL with wild-type VHL restored the cells’
ability to regulate or, more precisely, downregulate the ex-
pression of hypoxia-inducible genes in the presence of
oxygen [14,53,55–57]. The relative contribution of HIF-1 vs
HIF-2 (and,more recently, HIF-3) to RCC is an emerging area
of research. The introduction of an HIF-1a mutant that
escapes VHL recognition into RCC cells reconstituted with
wild-type VHL does not produce a tumorigenic phenotype in
SCID mice [58]. However, the treatment of these VHL-
restored RCC cells with an HIF-1a ODD peptide that can
block VHL binding to HIFa substrates restored the tumori-
genic phenotype [58]. This finding suggests that, although
HIF-1a is dispensable, other HIFa subunits (or other ECV
substrates) are associated with the tumor-suppressor func-
tion of VHL. In support of this notion, Kondo et al. [59]
demonstrated that, unlike HIF-1a, nondegradable HIF-2a
was able to restore the tumor phenotype in RCC cells
expressing wild-type VHL. This suggests that HIF-2a is
the relevant oncogenic player in the development of RCC.
Interestingly, VHL mutations affecting HIF regulation were
predominantly associated with the development of heman-
gioblastoma and RCC, but not pheochromocytoma [35,60].
For example, VHL mutants associated with type 2C VHL
disease (i.e., exclusive development of pheochromocytoma)
were shown to have ‘‘normal’’ E3 ubiquitin ligase activity and
to retain proper HIF function [35,60]. These mutants, how-
ever, were incapable of binding and regulating the assembly
of fibronectin ECM [35,60].
Mouse Model of VHL Disease
Conventional knockout of VHL in mice results in embryonic
lethality due to defective placental vasculature, precluding
the study of VHL inactivation/disease in adults [61]. There-
fore, to generate a mouse model to study VHL disease,
Rankin et al. [62] used the phosphoenolpyruvate carboxy-
kinase (PEPCK) promoter to generate transgenic mice in
which Cre-recombinase is expressed in renal proximal tu-
bules and hepatocytes. Conditional inactivation of VHL in
PEPCK-Cre mice resulted in glomerular and tubular renal
cysts, increased serum EPO levels, and polycythemia [62].
Notably, elevation of EPO level was limited to the liver,
whereas HIF downstream genes carbonic anhydrase 9 and
multidrug resistance gene 1 were increased in the renal
cortex. The inactivation of ARNT, but not HIF-1a, prevented
conditional VHL knockout mice from developing renal cysts
[62,63], further supporting the notion that another partner of
ANRT (such as HIF-2a, but not HIF-1a) is the relevant onco-
genic player in the transformation of renal proximal tubules.
Development of renal cysts in mice on VHL inactivation is
similar to the human condition wherein loss of VHL has been
observed in preneoplastic cysts [5], and suggests that other
genetic events are required for the progression of premalig-
nant cysts to RCC.
Role of NEDD8 in ECV Function
The E3 function of SCF and SCF-like ECV is dependent on
the recruitment of their respective E2 ubiquitin-conjugating
enzyme (Cdc34 and UbcH5a, respectively). Cullins are scaf-
fold components of SCF/ECV, which, until recently, have
been identified as singular proteins covalently modified by
the ubiquitin-like molecule, NEDD8 [22,64]. NEDD8 is at-
tached to substrates in a manner analogous to a ubiquitin
conjugation process, requiring NEDD8-activating APP-BP1/
Uba3 enzyme (E1; NAE) and NEDD8-conjugating enzyme
UbcH12 (E2; NCE). Unlike the ubiquitin pathway that has
multiple E2s, the NEDD8 pathway, to date, has just one E2.
Importantly, the overall E3 ubiquitin ligase activity of the
yeast SCF is enhanced by covalent modification of the
Cullin orthologue Cdc53 by the NEDD8 orthologue, related-
to-ubiquitin 1 [65,66]. Similarly, the activity of the mammalian
SCFbTrCP and SCFSkp2 complexes is increased by neddyla-
tion of Cul1, which facilitates the ubiquitylation of InBa and
p27, respectively [67,68]. Accordingly, NEDD8 modification
of Cul2 enhances the activity of ECV in vivo [69].
In search formechanismsgoverningSCF function, the core
Cullin/Rbx1 complex was shown to be required for the recruit-
ment of Cdc34 by the yeast SCF [27,70]. Subsequently, the
neddylated Cul1/Rbx1 complex was demonstrated to be sig-
nificantly better at supporting the Cdc34-mediated assembly
of polyubiquitin chains than the unneddylated Cul1/Rbx1
counterpart [71]. In support, NEDD8 modification of Cul1
was shown to directly enhance the binding of ubiquitin-
conjugated E2 Ubc4 to SCFbTrCP [72]. In addition, p120CAND1
was identified to interact selectively with unneddylated Cul1
to cause Skp1 dissociation from the SCF complex. Con-
versely, neddylation of Cul1 prevented p120CAND1 binding, al-
lowing SCF complex formation and activity [73–75]. However,
it is unlikely that p120CAND1 or p120CAND1-like protein is in-
volved in the NEDD8-dependent assembly of ECV because
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unneddylated Cul2 is also found in the ECV complex with-
out causing the dissociation of VHL from the complex (M. Ohh,
unpublished data). Although these reports reveal important
insights into the NEDD8-mediated regulation of SCF, it is
not entirely clear how the timing of E2 recruitment is coor-
dinated with the engagement of the substrate through the
F-box protein.
In addition to UbcH12, the NEDD8 modification of Cul2
requires Rbx1, which suggests Rbx1 to be an E3 NEDD8
ligase (R. I. Sufan and M. Ohh, unpublished data). Neddy-
lated Cul2 preferentially binds UbcH5a (R. I. Sufan and M.
Ohh, unpublished data). Interestingly, HIFa-engaged ECV
preferentially contains neddylated Cul2, whereas ECV, con-
sisting of mutant VHL incapable of recruiting HIFa, exclu-
sively associates with unmodified Cul2 (R. I. Sufan and M.
Ohh, unpublished data). These results support the notion that
the oxygen-dependent binding of HIFa through VHL triggers
Rbx1-mediated neddylation of Cul2, which promotes the
engagement of UbcH5a to the ECV complex, thereby estab-
lishing a central role for the neddylation of Cul2 in the
temporally coordinated activation of ECVwith the recruitment
of its substrate, HIFa. However, it is not yet known how
the binding of HIFa triggers the NEDD8-mediated activation
of ECV.
Emerging Models of HIF-Mediated Death and Adhesion
VHL-Associated Death Function
Tumors with elevated hypoxic tissue profile pose a serious
problem to the efficacy of conventional radiation therapy and
chemotherapy. Global gene expression profiling has re-
vealed that RCC cells display VHL-dependent sensitivity to
tumor necrosis factor (TNF) a–mediated cytotoxicity [76].
Reconstitution of RCC (VHL/) cells with wild-type VHL
restored their sensitivity to TNFa cytotoxicity, at least in part,
by downregulating the level of nuclear factor (NF) nB in the
nucleus, resulting in the attenuated expression of NF-nB
target antiapoptotic genes c-FLIP, Survivin, c-IAP-1, and
c-IAP-2, which block the activities of caspases 8 and 3 [77].
Recently, An and Rettig [78] showed that the activation of
NF-nBon the loss of VHLwas dependent on theHIF pathway,
which induces the expression of TGFa, with consequent
activation of the EGFR/PI3–OH kinase/AKT/InB kinase
a/NF-nB signaling cascade. In keeping with the model of a
classic tumor suppressor, VHL has a proapoptotic function
that is HIF-mediated.
In contrast, Devarajan et al. [79] showed that, in compar-
ison to VHL cells, VHL+ cells display an upregulated ex-
pression of Bcl-2, reduced activation of caspase 9, and
release of cytochrome c into the cytosol following chemical
hypoxia. Thus, in this setting, VHL seems to have an anti-
apoptotic function. Although counterintuitive, the authors
speculate that the loss of VHL may increase the sensitivity
of cells to physiologic stresses, which may foster selective
pressure for cells to circumvent death under such conditions.
The clonal outgrowth of VHL cells may then acquire addi-
tional genetic mutations contributing to neoplastic transfor-
mation. It is unknown whether the antiapoptotic function of
VHL is HIF-dependent.
VHL-Associated Adhesion Function
VHL negatively regulates the activity of HIF, and failure in
this regulation leads to tumor development in experimental
settings. However, how or why the deregulation or, more
precisely, the overactivation of HIF leads to tumorigenesis
is still unclear. Krishnamachary et al. [80] and Esteban et al.
[81] independently showed that the loss of VHL in RCC
cells results in the loss of E-cadherin in an HIF-dependent
manner. E-cadherins, homophilic adhesion molecules, and
their associated catenins are the major constituents of cell
junctions in polarized epithelial cells [82]. Increased expres-
sion of E-cadherin is associated with the differentiation
of mesenchymal cells into tubular epithelial cells of adult
nephrons. Conversely, loss of cell–cell adhesion is fre-
quently associated with tumor progression, metastasis, and
poor prognosis [82]. In support of this dogma, the loss of
E-cadherin is associated with the progression of numerous
carcinoma types [82]. Forced expression of E-cadherin
suppresses tumor development and invasion in various
in vitro and in vivo tumor model systems, establishing E-
cadherin as a critical tumor suppressor of the epithelium [82].
Thus, HIF-dependent repression of E-cadherin in RCC,
devoid of VHL, may provide the formerly ‘‘missing’’ biologic
basis for the development, as well as the aggressive nature,
of RCC.
This is not without some controversy. Krishnamachary
et al. [80] argued that the regulation of E-cadherin expression
is exclusively HIF-1–dependent, as it failed to see the
recovery of E-cadherin level when 786-O cells, which were
HIF-1, were reconstituted with wild-type VHL. However,
Esteban et al. [81], using RCC4 (HIF-1a+/+; HIF-2a+/+) and
786-O (HIF-1a/; HIF-2a+/+) cells, demonstrated depen-
dency on both HIF-1 and HIF-2. In addition, activation of
the HIF pathway on the loss of VHL transactivates the
E-cadherin transcriptional repressors TCF3 (also known as
E12/E47), ZFHX1A (yEF1 or ZEB1), and ZFHX1B (also
known as SIP1 or ZEB2), which result in the downregulation
of E-cadherin transcription [80]. Our group has observed a
similar induction of E-cadherin transcriptional repressors on
HIF-1 and/or HIF-2 activation, including ZFHX1B/SIP1 and
Snail, but no significant changes on TCF3 or ZFHX1A were
observed (A. J. Evans, O. R. Losada, R. C. Russell, and M.
Ohh, unpublished data).
Recently, Calzada et al. [83] have shown that the intro-
duction of wild-type VHL in RCC (VHL/) cells restores
the assembly of intercellular junctions through an HIF-
independent mechanism to promote the establishment of
an epithelial-like cell shape in otherwise fibroblastic-like
RCC cells. Kurban et al. [84] reported that the loss of ECM
assembly correlates with increased tumor angiogenesis and
matrix metalloproteinase-2 activity. Surprisingly, the loss of
HIF regulation in RCC cells, while resulting in tumors with
increased VEGF levels, displayed low microvessel density,
tightly assembled ECM, and low invasive potential [84].
These results suggest that the loss of ECM integrity promotes
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tumor angiogenesis by providing a route for blood vessels to
infiltrate the tumor.
VHL–p53 Connection
Recently, Roe et al. [85] reported an unexpected connection
between p53 and VHL. VHL was shown to directly bind and
stabilize p53 by suppressing Mdm2-mediated ubiquitination.
VHL also induced the acetylation of p53 on genotoxic stress
by promoting p53–p300 interaction, resulting in increased
p53 transcriptional activity and p53-mediated cell cycle arrest
and apoptosis [85]. This is truly a surprising finding given that
VHL was shown previously to have negligible effect on the
expression level of p53 in RCC cells [86]. Further indepen-
dent validation will be critical to determine the role of VHL
in p53 function.
Summary
As tumors grow, the diffusional capacity of oxygen from the
nearest blood vessel is inevitably surpassed, creating pock-
ets of hypoxia within the tumor. The hypoxic microenviron-
ment triggers the stabilization, as well as the increased
translation (through the mammalian target of rapamycin
[mTOR]), of HIFa. HIFa binds to the constitutively expressed
and stable ARNT to form an active HIF transcription factor
that initiates the transcription of genes containing HREs
within the promoter/enhancer regions. HIF-driven gene tran-
scripts responsible for, but not limited to, the promotion of
neovascularization, anaerobic metabolism, and cell survival
are expressed in adaptation to the reduced and often com-
promised oxygen availability, underscoring the importance
of HIF in the survival, growth, and metastasis of tumors. Not
surprisingly, the degree of tumor hypoxia correlates with poor
prognosis, as well as with resistance to conventional anti-
cancer therapies.
VHL or ECV (elongins/Cul2/VHL) is the major regulator of
HIF by determining the stability of the catalytic HIFa subunit.
ECV selectively targets HIFa that has undergone prolyl
hydroxylation by PHDs in the presence of oxygen. Thus,
ubiquitin-mediated destruction of HIFa occurs only under
normoxic conditions. Interestingly, the engagement of HIFa
to VHL is temporally coordinated with the neddylation of Cul2
through UbcH12 and Rbx1. The neddylated Cul2 then binds
UbcH5a, which polyubiquitylates HIFa. Tumor hypoxia or
inactivating mutation in VHL results in the stabilization of
HIFa and in the consequential activation of HIF, triggering
the expression of genes that ultimately drive neoplastic
transformation—from loss of cell–cell contact inhibition, to
dedifferentiation, to tipping of the balance toward survival
over death (Figure 1).
Elucidation of HIF-dependent functions of VHL/ECV has
revealed an unprecedented wealth of knowledge on the
oxygen-sensing pathway and the pathophysiology of solid
tumor development. Such information has afforded novel
‘‘smarter’’ avenues of anticancer strategies directed against
important molecular targets revealed along the VHL–HIF
pathway [87]. Imagine what we can learn from deciphering
the other yet-defined HIF-dependent and HIF-independent
tumor-suppressor functions of VHL.
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